Anna Wijatyk, M.D., Chief Medical Officer Oct. 12 | 2:30pm | Oxford Biomedica Ballroom   Waltham, MA  (Private)  In-person Presentation  Miltenyi Biomedicine is a newly established biopharmaceutical company that develops innovative cell and gene therapies. We are committed to bringing cancer treatments and regenerative therapies to patients worldwide.  www.miltenyibiomedicine.com ...

Jeff Ross, Ph.D., CEO  Oct. 12 | 3:30pm | Oxford Biomedica Ballroom  Eden Prairie, MN  (NASDAQ: MIRO)  In-person Presentation  Miromatrix is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The company has developed a proprietary perfusion technology platform...

Kristi Jones, Pharm.D., CEO Oct. 11 | 5:00pm | Oxford Biomedica Ballroom   Gaithersburg, MD  (NASDAQ: NEXI)  In-person Presentation  NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology that uses natural biology to orchestrate a targeted cell-mediated immune response across a broad...

Shankar Musunuri, Ph.D., Co-founder, Chairman and CEO Oct. 12 | 2:00pm | UBC Ballroom   Malvern, PA  (NASDAQ: OCGN)  In-person Presentation  Ocugen is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines that improve health and offer hope for people and global communities. We are...

Kevin Caldwell, Co-founder and CEO Oct. 11 | 2:00pm | Oxford Biomedica Ballroom   San Francisco, CA  (Private)  In-person Presentation  Ossium Health has developed a proprietary technology to recover bone marrow stem cells from deceased organ donors. With this platform, we treat hematologic malignancies: Ossium is working to enable transplants for...

Steven Yatomi-Clarke, CEO Oct. 12 | 11:20am | Oxford Biomedica Ballroom   Melbourne, Australia  (ASX: PTX)  In-person Presentation  Prescient Therapeutics has two novel cell therapy platform technologies. OmniCAR is a universal immune receptor platform enabling controllable T cell activity and multi-antigen targeting with a single cell product. OmniCAR is based on technologies...

Luke Henry, Chief Business Officer  Oct. 11 | 11:30am | Oxford Biomedica Ballroom  London, UK  (Private)  In-person Presentation  Quell Therapeutics is leading the emerging field of using engineered T-regulatory (Treg) cell therapies that aim to harness, direct, and optimize their immune suppressive properties to address serious medical conditions driven by the...

Kelly Kester, Director of Advanced Therapy Solutions  Oct. 12 | 4:15pm | Oxford Biomedica Ballroom  Dublin, OH  (NASDAQ: CAH)  In-person Presentation  Cardinal Health Advanced Therapy Solutions brings a unique understanding of the challenges of launching and commercializing cell and gene therapies (CGTs) — and how to overcome them effectively. Our early...

Karen Walker, Chief Technology Offiicer  Oct. 11 | 11:15am | Oxford Biomedica Ballroom  Emeryville, CA  (Private)  In-person Presentation  Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. We combine advanced T cell engineering and synthetic biology to target the underpinnings of autoimmunity:...

Derek Hicks, Chief Business Officer Oct. 11 | 11:15am | UBC Ballroom   Cambridge, MA  (NASDAQ: NTLA)  In-person Presentation  Intellia Therapeutics is a leading clinical-stage genome editing company, focused on developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. We are building a full-spectrum genome editing company, by leveraging our modular platform, to advance...

By using this website you agree to accept our Privacy Policy and Terms & Conditions